- This event has passed.
Genesis Lecture Series: Clinical Development Pathways
September 19 @ 4:00 pm - 5:00 pm
Nucleate Seattle is proud to announce our Genesis Lecture Series, an eight-part lecture series that will illuminate the path from conception to commercialization of life science companies!
Join us every Thursday throughout August and September as we cover topics relating to building a life science venture, intricacies of commercialization, protection of intellectual property and fundraising strategies.
We have a fantastic line-up of speakers for each lecture! They include experts from Seattle-based biotech companies like Ozette Technologies, Wavely Diagnostics and Parse Biosciences, and from local funding organizations like Pack VC and Alliance of Angels!
Lecture 7: Clinical Development Pathways
Nucleate Seattle is excited to announce we are hosting a panel on Clinical Development Pathways for biotech start-ups. Come gain insight into how biotech companies prepare for clinical validation and learn more about the FDA/health regulations that are required before bringing innovations to market! This event will provide practical advice on transitioning from academia to bio-entrepreneurship, and advice for starting companies to consider to make transitioning to clinical trials easier. Don’t miss this opportunity to learn from and network with industry leaders!
Date: September 19th at 4pm
Location: Buerk Center’s Founders Hall Room 406
RSVP here: https://lu.ma/60if8ynp
Check out our Genesis event page for a full list of topics and speakers, and register today!! This lecture series is focused on serving all Seattle-based trainees at any level and is completely free-to-attend!
Nucleate is a global student-run nonprofit organization that facilitates the formation of new life science ventures. Our mission is to empower the next-generation of biotech leaders through open-access biotech programming. Our flagship Activator program supports scientific trainees who plan to tackle the biggest challenges in human health by building life science startups